NKCx Histopathological outcome* within 12 months after cervix cytology in 2021 |
088 Region Stockholm |
Benign | LSIL | HSIL | AIS | Cancer | Other | PAD missing | Total | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cytologi | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
Benign sample | 498 | 7.9% | 177 | 2.8% | 104 | 1.6% | 1 | 0.0% | 3 | 0.0% | 26 | 0.4% | 5508 | 87.2% | 6317 | 100.0% |
ASCUS | 647 | 33.2% | 411 | 21.1% | 276 | 14.2% | 15 | 0.8% | 4 | 0.2% | 31 | 1.6% | 564 | 29.0% | 1948 | 100.0% |
LSIL | 387 | 29.6% | 360 | 27.6% | 249 | 19.1% | 1 | 0.1% | . | . | 12 | 0.9% | 297 | 22.7% | 1306 | 100.0% |
Atypical glandular cells/AGC | 24 | 20.7% | 21 | 18.1% | 45 | 38.8% | 9 | 7.8% | 4 | 3.4% | 3 | 2.6% | 10 | 8.6% | 116 | 100.0% |
Unclear atypia | 1 | 16.7% | 1 | 16.7% | 1 | 16.7% | . | . | . | . | . | . | 3 | 50.0% | 6 | 100.0% |
ASC-H | 47 | 18.5% | 47 | 18.5% | 128 | 50.4% | 4 | 1.6% | 2 | 0.8% | . | . | 26 | 10.2% | 254 | 100.0% |
HSIL | 35 | 9.8% | 36 | 10.1% | 217 | 60.8% | 3 | 0.8% | 5 | 1.4% | 3 | 0.8% | 58 | 16.2% | 357 | 100.0% |
Suspected Adenocarcinom | 1 | 5.0% | . | . | 2 | 10.0% | 4 | 20.0% | 4 | 20.0% | . | . | 9 | 45.0% | 20 | 100.0% |
Malignant tumor with unclear origin | . | . | . | . | 1 | 100.0% | . | . | . | . | . | . | . | . | 1 | 100.0% |
Squamous cell cancer | . | . | . | . | 1 | 50.0% | . | . | 1 | 50.0% | . | . | . | . | 2 | 100.0% |
Totalt | 1640 | 15.9% | 1053 | 10.2% | 1024 | 9.9% | 37 | 0.4% | 23 | 0.2% | 75 | 0.7% | 6475 | 62.7% | 10327 | 100.0% |
NOTE: Histopathological outcome from T83x taken into account. |
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
Snomed codes in the category Cancer: |
---|
M69760, M80703, M81403, M82003, M85603 |